Sabatelli, Lorenzo http://orcid.org/0000-0001-7373-9306
Keränen, Mikko
Viayna, Elisabet
Roset, Montserrat
Lara, Nuria
Thunström, Daniel
Pfeiffer, Minja
Nicklasson, Malin
Itälä-Remes, Maija
Funding for this research was provided by:
Incyte Corporation
Article History
Received: 31 August 2021
Accepted: 12 February 2022
First Online: 2 March 2022
Declarations
:
: The study was conducted in accordance with the protocol, good pharmacoepidemiology practices, and the ethical principles embodied by the Declaration of Helsinki and applicable privacy laws. Institutional review boards/independent ethics committees reviewed and approved the study protocol before any patients were enrolled.
: This was a retrospective chart review study using de-identified patient data; therefore, no consent was required.
: This was a retrospective chart review study using de-identified patient data; therefore, no consent was required.
: Lorenzo Sabatelli, Daniel Thunström, and Minja Pfeiffer are employees and shareholders of Incyte Biosciences International. Mikko Keränen has provided consulting services for Novartis, Amgen, Janssen-Cilag, Pfizer, and Incyte Corporation; has an ownership interest in Iovance Biotherapeutics (IOVA); and has received honoraria from Accord Healthcare, Astellas, AbbVie, Amgen, and Takeda. Elisabet Viayna, Montserrat Roset, and Nuria Lara are employees of IQVIA Real World Solutions. Malin Nicklasson and Maija Itälä-Remes report no conflicts of interest.
: Part of the results and methods of this manuscript were previously presented at Virtual ISPOR Europe 2020 (November 16–19, 2020).